Mitchell Horwitz, MD, on Cost-Effectiveness of Omidubicel for Allo-HCT


The professor of medicine at Duke Cancer Institute discussed uptake and research with the cord blood therapy since its approval.

"There is a little bit of training that the donor coordinator has to have to become familiar with the registration portal, which is quite similar to CAR-T registration. Once it's made available to the coordinators, it's quite straightforward about once the unit has been requested, a shipment date is determined and the patient's experience, as well as the transplant centers experience, is very similar to what they would experience with other cryopreserved grafts, which nearly all centers are very familiar with.”

Patients receiving allogeneic hematopoietic cell transplantation (alloHCT) with omidubicel had similar outcomes in a real-world early access program (EAP) to those enrolled in the phase 3 registrational study (NCT0273029) that supported its approval as Omisirge in April 2023.1,2

Data from the EAP were presented by Mitchell Horwitz, MD, professor of medicine and cell transplant specialist, Duke University Cancer Institute, at the 2024 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in San Antonio, Texas, February 21-24, 2024.

CGTLive® spoke with Horwitz to learn more about omidubicel and experience with it since its approval. He discussed how uptake may be slow of the newly approved therapy, butstressed its ease of administration as well as the theorized cost-effectniess of omidubicel.

View more coverage of the 2024 Tandem Meeting now.

1. Horwitz M, Schiller GJ, Tsai SB, et al. Omidubicel-Onlv for Allogeneic Transplantation (allo-HCT) in Patients with Hematologic Malignancies: Results of a Multicenter Open-Label Expanded Access Program (EAP). Presented at: 2024 Tandem Meetings, February 21-24, San Antonio, Texas. Abstract #313
2. FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation. News release. FDA. April 17, 2023. Accessed April 17, 2023.
Related Videos
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.